(BDX) Becton Dickinson - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 55.978m USD | Total Return: -11.2% in 12m

Stock Medical Devices, Diagnostics, Lab Equipment, Surgical Products
Total Rating 46
Risk 84
Buy Signal -0.69
Medical Instruments & Supplies -2.1
Health Care Equipment -3.7
Market Cap: 55,978m
Avg Trading Vol: 376M USD
ATR: 2.72%
Peers RS (IBD): 61.3
Risk 5d forecast
Volatility23.3%
Rel. Tail Risk-10.0%
Reward TTM
Sharpe Ratio-0.33
Alpha-21.39
Character TTM
Beta0.503
Beta Downside0.277
Drawdowns 3y
Max DD40.06%
CAGR/Max DD-0.13
EPS (Earnings per Share) EPS (Earnings per Share) of BDX over the last years for every Quarter: "2021-03": 3.19, "2021-06": 2.74, "2021-09": 2.59, "2021-12": 3.64, "2022-03": 3.18, "2022-06": 2.66, "2022-09": 2.75, "2022-12": 2.98, "2023-03": 2.86, "2023-06": 2.96, "2023-09": 3.42, "2023-12": 2.68, "2024-03": 3.17, "2024-06": 3.5, "2024-09": 3.81, "2024-12": 3.43, "2025-03": 3.35, "2025-06": 3.68, "2025-09": 3.96, "2025-12": 2.91,
EPS CAGR: -2.34%
EPS Trend: 60.2%
Last SUE: -2.35
Qual. Beats: 0
Revenue Revenue of BDX over the last years for every Quarter: 2021-03: 4907, 2021-06: 4607, 2021-09: 5135, 2021-12: 4718, 2022-03: 4750, 2022-06: 4641, 2022-09: 4761, 2022-12: 4586, 2023-03: 4821, 2023-06: 4878, 2023-09: 5087, 2023-12: 4706, 2024-03: 5045, 2024-06: 4990, 2024-09: 5437, 2024-12: 5168, 2025-03: 5272, 2025-06: 5509, 2025-09: 5890, 2025-12: 5252,
Rev. CAGR: 2.72%
Rev. Trend: 85.6%
Last SUE: 2.08
Qual. Beats: 1
Description: BDX Becton Dickinson

Becton, Dickinson and Company (NYSE: BDX) is a global medical technology firm that develops and manufactures a broad portfolio of medical supplies, laboratory equipment, and diagnostic products. Operating through segments such as Medical Essentials, Connected Care, and Life Sciences, the company produces foundational healthcare tools ranging from IV catheters and hypodermic syringes to advanced infusion pumps and automated medication dispensing systems. BDX benefits from a business model heavily reliant on high-volume consumables, creating recurring revenue streams alongside its capital equipment sales within the Health Care Equipment industry.

The company serves healthcare institutions, life science researchers, and the pharmaceutical industry with specialized technologies, including flow cytometry analyzers, molecular testing assays, and prefillable drug delivery systems. Its surgical and interventional offerings encompass soft tissue repair grafts, infection prevention products, and urology solutions. BDX also maintains strategic collaborations, such as its partnership with ChemoGLO, to enhance safety protocols regarding hazardous drug contamination. For comprehensive data on BDXs financial performance and fair value estimates, investors can check ValueRay.

Headlines to Watch Out For
  • Medical Essentials segment revenue growth drives stock performance
  • Regulatory approvals for new devices impact sales
  • Global healthcare spending trends influence demand
  • Supply chain disruptions increase manufacturing costs
Piotroski VR‑10 (Strict) 5.5
Net Income: 1.76b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0
NWC/Revenue: 1.95% < 20% (prev 4.82%; Δ -2.87% < -1%)
CFO/TA 0.06 > 3% & CFO 3.39b > Net Income 1.76b
Net Debt (18.52b) to EBITDA (5.10b): 3.63 < 3
Current Ratio: 1.05 > 1.5 & < 3
Outstanding Shares: last quarter (285.1m) vs 12m ago -1.83% < -2%
Gross Margin: 45.76% > 18% (prev 0.45%; Δ 4.53k% > 0.5%)
Asset Turnover: 40.04% > 50% (prev 37.76%; Δ 2.28% > 0%)
Interest Coverage Ratio: 4.65 > 6 (EBITDA TTM 5.10b / Interest Expense TTM 565.0m)
Altman Z'' 1.91
A: 0.01 (Total Current Assets 9.19b - Total Current Liabilities 8.76b) / Total Assets 54.84b
B: 0.30 (Retained Earnings 16.70b / Total Assets 54.84b)
C: 0.05 (EBIT TTM 2.63b / Avg Total Assets 54.75b)
D: 0.52 (Book Value of Equity 15.24b / Total Liabilities 29.56b)
Altman-Z'' Score: 1.91 = BBB
Beneish M -3.12
DSRI: 0.90 (Receivables 2.51b/2.64b, Revenue 21.92b/20.64b)
GMI: 0.99 (GM 45.76% / 45.22%)
AQI: 0.98 (AQ_t 0.71 / AQ_t-1 0.72)
SGI: 1.06 (Revenue 21.92b / 20.64b)
TATA: -0.03 (NI 1.76b - CFO 3.39b) / TA 54.84b)
Beneish M-Score: -3.12 (Cap -4..+1) = AA
What is the price of BDX shares? As of April 03, 2026, the stock is trading at USD 157.23 with a total of 1,769,376 shares traded.
Over the past week, the price has changed by -1.82%, over one month by -11.92%, over three months by +1.46% and over the past year by -11.16%.
Is BDX a buy, sell or hold? Becton Dickinson has received a consensus analysts rating of 3.59. Therefor, it is recommend to hold BDX.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BDX price?
Wallstreet Target Price 196.1 24.7%
Analysts Target Price 196.1 24.7%
BDX Fundamental Data Overview as of 31 March 2026
P/E Trailing = 25.2467
P/E Forward = 12.3153
P/S = 2.5533
P/B = 1.7385
P/EG = 1.1953
Revenue TTM = 21.92b USD
EBIT TTM = 2.63b USD
EBITDA TTM = 5.10b USD
Long Term Debt = 16.92b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from shortTermDebt, last quarter)
Debt = 19.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.52b USD (from netDebt column, last quarter)
Enterprise Value = 74.78b USD (55.98b + Debt 19.54b - CCE 740.0m)
Interest Coverage Ratio = 4.65 (Ebit TTM 2.63b / Interest Expense TTM 565.0m)
EV/FCF = 28.42x (Enterprise Value 74.78b / FCF TTM 2.63b)
FCF Yield = 3.52% (FCF TTM 2.63b / Enterprise Value 74.78b)
FCF Margin = 12.00% (FCF TTM 2.63b / Revenue TTM 21.92b)
Net Margin = 8.01% (Net Income TTM 1.76b / Revenue TTM 21.92b)
Gross Margin = 45.76% ((Revenue TTM 21.92b - Cost of Revenue TTM 11.89b) / Revenue TTM)
Gross Margin QoQ = 44.63% (prev 47.50%)
Tobins Q-Ratio = 1.36 (Enterprise Value 74.78b / Total Assets 54.84b)
Interest Expense / Debt = 0.55% (Interest Expense 107.0m / Debt 19.54b)
Taxrate = 21.56% (105.0m / 487.0m)
NOPAT = 2.06b (EBIT 2.63b * (1 - 21.56%))
Current Ratio = 1.05 (Total Current Assets 9.19b / Total Current Liabilities 8.76b)
Debt / Equity = 0.77 (Debt 19.54b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 3.63 (Net Debt 18.52b / EBITDA 5.10b)
Debt / FCF = 7.04 (Net Debt 18.52b / FCF TTM 2.63b)
Total Stockholder Equity = 25.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.21% (Net Income 1.76b / Total Assets 54.84b)
RoE = 6.93% (Net Income TTM 1.76b / Total Stockholder Equity 25.35b)
RoCE = 6.22% (EBIT 2.63b / Capital Employed (Equity 25.35b + L.T.Debt 16.92b))
RoIC = 4.61% (NOPAT 2.06b / Invested Capital 44.68b)
WACC = 5.86% (E(55.98b)/V(75.52b) * Re(7.75%) + D(19.54b)/V(75.52b) * Rd(0.55%) * (1-Tc(0.22)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.09%
[DCF] Terminal Value 87.39% ; FCFF base≈2.75b ; Y1≈3.08b ; Y5≈4.10b
[DCF] Fair Price = 357.8 (EV 120.30b - Net Debt 18.52b = Equity 101.78b / Shares 284.5m; r=6.0% [WACC]; 5y FCF grow 13.83% → 3.0% )
EPS Correlation: 60.25 | EPS CAGR: -2.34% | SUE: -2.35 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 2.72% | SUE: 2.08 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.07 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-7 | Analysts=11
EPS current Year (2026-09-30): EPS=12.46 | Chg7d=+0.008 | Chg30d=-0.082 | Revisions Net=-10 | Growth EPS=-13.5% | Growth Revenue=-12.3%
EPS next Year (2027-09-30): EPS=13.51 | Chg7d=+0.015 | Chg30d=+0.023 | Revisions Net=-11 | Growth EPS=+8.5% | Growth Revenue=+2.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = -14.8% (Analyst -10.8% - Implied 4.0%)
External Resources
Dataroma Stockcircle